Team Members
-
Kasper Glavind Hedegaard
Kasper Glavind Hedegaard Senior Associate -
Declan Warwick
Declan Warwick Associate Director -
Hamish Scott
Hamish Scott Associate
交易
-
Clearwater顾问
Adviser to Medichem on its acquisition of a majority stake in Ruick Pharma
页面
-
Following the publication of the Q3 2021 Clearwater International Multiples Heatmap, Unquote interviewed Clearwater’s executive team to discuss valuation trends in European private equity.
-
Mid-market advisory firm Clearwater International completed a record breaking 106 deals worth over €9 billion in 2016 – a deal value increase of over 120% from 2015; average deal values also nearly doubled during the period.
-
A high-growth and resilient market characterised by high levels of M&A activity from both trade buyers and private equity.
-
CROs are constantly expanding their addressable markets by broadening their service offerings, capturing an increasing share of pharma R&D expenditure. Investment in technology and big data will continue to play an important role in the expansion of the CRO sub-sector.
-
CCOs offer a broad range of commercialisation services to their customers, typically focussed on preparing new products for launch and maximising sales post approval.
-
TMT was the hottest sector in Q2 2018 at 13.0x and over the last six quarters with an average multiple of 11.3x. DACH and Nordic regions drove this trend with TMT valuations in those regions increasing to 12.8x and 12.1x respectively.
-
TMT was the hottest sector in Q2 2018 at 13.0x and over the last six quarters with an average multiple of 11.3x. DACH and Nordic regions drove this trend with TMT valuations in those regions increasing to 12.8x and 12.1x respectively.
-
Mid-market advisory firm Clearwater International completed 129 deals in the last financial year with average deal values increasing by 31%, placing Clearwater in 7th place in the Pan-European financial advisors league tables.
